Related by context. Frequent words. (Click for all words.) 64 Idera Pharmaceuticals develops 61 selectively induce apoptosis 57 nitric oxide donating 57 Lu AA# 57 Currently RegeneRx 57 Panzem 56 ARIAD vision 56 inhibit angiogenesis 56 intranasal delivery 56 TLR8 56 CTLA4 Ig 56 promising anticancer 55 synthetic retinoid 55 Inc. Nasdaq INFI 54 medicinal chemists 54 genomic proteomic 54 synthetic peptides 54 novel anticancer 54 ZFP Therapeutics 54 theranostic 53 staphylococcal vaccines 53 please visit www.rosettagenomics.com 53 Litx 53 lentiviral vectors 53 MedImmune strives 53 potent anticancer 52 http:/sports.forsythnews.com/ encourages readers 52 BioLeap 52 MEK inhibitors 52 viral proteins 52 Synavive 52 Aplidin 52 TaiGen 52 chromatin structure 52 ZFP technology 52 partial agonist 52 cytoprotective 52 metabolic enzymes 52 mPhase Smart NanoBattery 51 Cylene 51 diagnostic biomarkers 51 EARNINGS WATCH Updates advisories 51 hedgehog pathway 51 chemical entities NCEs 51 Neo Kidney Augment 51 AutovaxID 51 regulate therapeutically important 51 Updates advisories 51 neurotrophic 51 GVAX cancer 51 Alnylam dependence 51 cellular pathways 51 biologically validated targets 51 cancer immunotherapies 51 ACh 50 hESC derived 50 HMG CoA reductase 50 selectively inhibit 50 teplizumab 50 Mipomersen 50 preclinical compounds 50 vascular disrupting agent 50 oncogenesis 50 glycomics 50 Lupuzor 50 targeted resequencing 50 galanin 50 iPSC 50 neurochemistry 50 CMV vaccine 50 dissolve blood clots 50 neuromuscular junction 50 biocatalysts 50 cells hESCs 50 peptide hormone 50 Zafgen 50 splice variants 50 proteins peptides 50 bioimaging 50 potent inhibitors 49 antisense RNA 49 Wnt signaling pathway 49 physiologically relevant 49 identify protein biomarkers 49 molecular underpinnings 49 Rosetta dependence 49 macromolecular 49 PARP inhibitors 49 nicotinic receptor 49 immunogens 49 Alzhemed TM 49 oral anticancer 49 act synergistically 49 ProSavin 49 PTP1B 49 cellular signaling pathways 49 inhibiting tumor 49 neuronal circuits 49 motesanib 49 Omapro 49 novel antibody therapeutics